Parent Briefing: Independent Evidence Review Affirms Flu, RSV, and COVID Protection for Infants — Clinic Asks for October 16, 2026

## What parents need to know today

An independent evidence review released this week by the Vaccine Integrity Project and the American Medical Association confirms that influenza, RSV, and COVID-19 immunizations continue to provide meaningful protection for infants and children against severe illness, hospitalization, and death. No new pediatric safety signals were identified.

### Key numbers for parents

- Influenza vaccination was **80% effective** against laboratory-confirmed flu death in children 6 months to 17 years across eight surveillance seasons.
- Maternal vaccination for flu, COVID-19, and RSV each extends measurable protection to infants in the first months of life.
- Nirsevimab (Beyfortus) reduced RSV hospitalization risk by **64–93%** in an infant’s first season.
- Maternal RSV vaccination reduced infant hospitalization risk by **51–70%**.

### What changed

The review screened thousands of studies published primarily between August 2025 and June 2026. It informed the 2026–27 respiratory virus immunization recommendations issued jointly by the AAP, AAFP, ACOG, and IDSA. This comes amid ongoing discussions about advisory committee processes and the value of independent reviews for clinical guidance.

### Competing viewpoints

Some parents and clinicians prioritize the large body of real-world evidence showing protection against severe outcomes. Others note remaining evidence gaps (for example, duration of RSV vaccine protection in older adults) and prefer shared decision-making at the individual level. The review itself found no new safety concerns in comparative studies of currently recommended immunizations.

### What to watch next

- Clinic conversations about maternal RSV vaccine (Abrysvo) timing and nirsevimab eligibility for infants entering their first season.
- Expanded second-season nirsevimab criteria for certain high-risk children ages 8–19 months.
- Local respiratory virus activity as flu and RSV seasons ramp up.
- Any further updates from AAP or CDC on 2026–27 guidance.

**Clinic asks this week:** Ask whether your infant qualifies for nirsevimab if born during or entering the first RSV season and the pregnant parent did not receive Abrysvo ≥14 days before delivery. Confirm flu vaccine status for everyone 6 months and older in the household. Discuss COVID vaccination for children 6–23 months if not already completed.

Sources: Vaccine Integrity Project / AMA independent evidence review (2026); Contemporary Pediatrics coverage; AAP 2026–27 respiratory recommendations.

*This is general information, not medical advice. Talk with your clinician about what fits your family.*